Osteoarthritis, Knee
Conditions
Keywords
Fisetin, Inflammation, Osteoarthritis
Brief summary
Phase I/II randomized, double-blind, placebo-controlled clinical trial to test the safety and efficacy of Fisetin for treating mild to moderate osteoarthritis
Detailed description
This is a Phase I/II randomized, double-blind, placebo-controlled clinical trial that will be conducted at The Steadman Clinic (TSC) and Steadman Philippon Research Institute (SPRI). The purpose of this study is to evaluate the clinical efficacy of Fisetin (FIS), a dietary supplement, in symptomatic knee osteoarthritis (OA) patients. Key aspects of this proposal include the investigator's well-developed methodologies to measure and compare systemic senescence-associated secretory phenotype (SASP) including inflammatory biomarkers and senescent cells, and collect magnetic resonance images, self-reported outcomes, physical performance and other objective clinical data. Given the drug FIS has been empirically demonstrated to reduce senescent cell burden, the main objective(s) are to determine 1) the safety of FIS during dosing and 2) whether FIS reduces senescent cells, pro-inflammatory and cartilage degenerating SASP markers, and reduces OA-symptoms leading to improved joint health and function.
Interventions
DIETARY_SUPPLEMENTFisetin
Fisetin will be administered orally at 20 mg/kg for two consecutive days, followed by 28 days off, then 2 more consecutive days.
DRUGPlacebo oral capsule
Placebo will be administered orally for two consecutive days, followed by 28 days off, then 2 more consecutive days.
Sponsors
United States Department of Defense
Office of Naval Research (ONR)
Steadman Philippon Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Subjects will be included if all the following criteria are met: 1. Are male or female, ages 40-80; 2. Are willing to comply with all study related procedures and assessments; 3. Are ambulatory as defined by ability to complete functional performance testing; 4. Radiographic evidence of Kellgren-Lawrence grade II-IV osteoarthritis in one or both knees; 5. Scores 4-10 on the Numerical Rating Scale (NRS) for pain; 6. Stable dose of screening/baseline medications for at least 2 months prior to the anticipated date of study drug dosing.
Exclusion criteria
Subjects will be excluded if any of the following criteria are met: 1. Females who are nursing, pregnant or planning to become pregnant during the duration of study drug dosing; 2. Males who do not wish to abstain from sex or use contraceptive protection during study drug dosing and for 2 weeks after the last dose; 3. Subjects who do not have the capacity to consent themselves; 4. Subjects who are unable to tolerate oral medication; 5. Subjects having previously undergone any of the following treatments in the stated time window. * Surgery on the Study Knee in the past 6 months; * Partial or complete joint replacement in the study knee. Partial or complete joint replacement in the contralateral knee is acceptable as long as the surgery was performed at least 6 months prior to enrollment and the operative knee is asymptomatic; * Patients who have undergone arthroscopic surgery (including microfracture and meniscectomy) on the Study Knee in the last 2 years prior to the Screening visit or are anticipated to have arthroscopic surgery on either knee at any time during the study period; * Steroid injection, including extended-release corticosteroid (e.g., Zilretta®) within the last 5 months; * Biologic (platelet-rich plasma, bone marrow, adipose tissue/cells) or hyaluronic acid injection into the Study Knee in the past 6 months; 6. Subjects with any of the following drug/medication statuses: * Currently taking Losartan; * Currently taking Warfarin or related anticoagulants; * Opioid analgesics taken in the past 8 weeks and are not willing to discontinue these medications through the duration of the study; * Senolytic agents taken within the past 6 months and are not willing to discontinue these medications through the duration of the study, including: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax; * Drugs that induce significant cellular stress and are not willing to discontinue these medications through the duration of the study, including alkylating agents, anthracyclines, platins, other chemotherapy drugs; * Subjects taking the following other drugs if they cannot be held (per the Principal Investigator) for at least 2 days before and during administration of Fisetin: cyclosporine, tacrolimus, repaglinide, and bosentan. 7. Subjects with any of the following disease statuses: * Significant liver disease (i.e. greater than or equal to 2x the upper limit of normal bilirubin levels) or as in the opinion of the Principal Investigator; * Significant renal disease (eGFR of \<60 ml/min/1.73m2) or as in the opinion of the Principal Investigator; * History of other formally diagnosed joint diseases including osteonecrosis, acromegaly, Paget's disease, Ehlers-Danlos Syndrome, Gaucher's disease, Cushing's syndrome, Stickler's syndrome, joint infection, hemophilia, hemochromatosis, or neuropathic arthropathy of any cause; * Any active systemic autoimmune disease with musculoskeletal involvement or any history of system inflammatory arthritis; * Patients with type 1 or 2 diabetes (HbA1c\>6.5%) and/or taking medications that affect insulin levels, including: Metformin (within the last week), Glucocorticoids (within the last month), Acarbose (within the last week); 8. Subjects unable to safely practically undergo an MRI (BMI \> 40 kg/m2) or size exceeding limits of MRI equipment, implanted metal in study knee near joint surface, incompatible implant/device, severe claustrophobia; 9. Subjects that have any medical condition, including laboratory findings and findings in the medical history or in the pre-study assessments, that in the opinion of the Investigator constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct or evaluation or prevent the patient from fully participating in all aspects of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Experiencing One or More Treatment-Emergent Adverse Event | Duration of study, an average of 12 months | Number of Participants Experiencing one or more Treatment-Emergent Adverse Event (TEAE) within each group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Levels of Cartilage Degenerating Markers Associated With OA | 14 days, 45 days, 6 months, 12 months (post 1st drug dose) | Serum cartilage oligomeric matrix protein (COMP) level measured on ELISA. All post-intervention group comparisons were adjusted for the baseline value as a covariate. |
| Change in Physical Function of the Study Knee (6 Min Walk) | 6 months, and 12 months (post 1st drug dose) | The 6 minute walk test (6MWT) assesses distance (in meters) walked over 6 minutes as a sub-maximal test of aerobic capacity, exercise tolerance and endurance. The score range for healthy adults is 400-700 m, depending on age and sex. Shorter distances indicate increased impairment. All post-intervention group comparisons were adjusted for the baseline value as a covariate. |
| Change in Physical Function of the Study Knee (Timed-up-and-go Test) | 6 months, and 12 months (post 1st drug dose) | The Timed Up and Go (TUG) test measures how long it takes (in seconds) to stand up, walk a distance of 10 feet, turn, walk back, and sit down again. \< 10 seconds is considered normal. Longer times indicate poorer function. All post-intervention group comparisons were adjusted for the baseline value as a covariate. |
| Change in Physical Function of the Study Knee (Fast 4-meter Walk) | 6 months, and 12 months (post 1st drug dose) | fast 4-meter walk test (4MW). The 4MW was assessed at the fastest safe speed for each participant. This test assesses the capacity for performance of certain activities (e.g., crossing a street before the light changes). Units are m/s, and slower speeds indicate greater impairment. All post-intervention group comparisons were adjusted for the baseline value as a covariate. |
| Change in Physical Function of the Study Knee (LEK) | 6 months, and 12 months (post 1st drug dose) | Peak knee adduction moment (KAM) during stance phase of gait in the affected leg, determined using video-motion analysis and force plate data. Values are normalized by mass\*height of participant. Higher KAM has been associated with more rapid osteoarthritis progression. All post-intervention group comparisons were adjusted for the baseline value as a covariate. |
| Change in Levels of Pro-inflammatory Markers Associated With Senescence | 14 days, 45 days, 6 months, 12 months (post 1st drug dose) | Serum C-reactive protein (CRP) level measured on ELISA. The enzyme linked immunoassay (ELISA) is a laboratory technique that detects certain antigens in the blood. ELISA was used to detect the level of CRP in the blood. The liver releases CRP into blood in response to inflammation. All post-intervention group comparisons were adjusted for the baseline value as a covariate. |
| Change in Muscle Strength (Isokinetic Dynamometry) | 6 months, and 12 months (post 1st drug dose) | This test utilizes an isokinetic dynamometer to assess the peak knee extension torque that can be produced by the affected leg at a constant rate of knee extension (60 degrees/s). The resulting measure is normalized by body mass and reported with units Newton-meters (Nm). Increased torque over time would indicate improved muscle strength and/or decreased joint pain. All post-intervention group comparisons were adjusted for the baseline value as a covariate. |
| Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | every 3 days for the first 6-weeks of drug dosing, then weekly for an additional 6 weeks. | Numeric Rating Scale (NRS) reporting 'pain today'. Scale of 0-10 with 0 representing 'no pain' and 10 representing 'severe pain'. All post-intervention group comparisons were adjusted for the baseline value as a covariate. |
| Evaluation of Patient Reported Outcomes (PROs) for Knee Function | 6 months, 12 months, and 18 months (post 1st drug dose) | Western Ontario and McMaster Universities Arthritis Index (WOMAC) - total score. Scores range from 0 to 96 for the total WOMAC where 0 represents the best health status and 96 the worst possible status. The higher the score, the poorer the function. All post-intervention group comparisons were adjusted for the baseline value as a covariate. |
| Change in the Quality of Articular Cartilage in the Study Knee With Quantitative Magnetic Resonance Imaging (MRI) | 6 months, and 12 months (post 1st drug dose) | Mean T2 relaxation times were determined across 4 subregions: central medial femur (CMF), central lateral femur (CLF), central medial tibia (CMT), and central lateral tibia (CLT). All post-intervention group comparisons were adjusted for the baseline value as a covariate. The mean T2 changes over time for all subregions were listed in rank order from most positive (indicating worsened cartilage condition over time) to most negative (indicating improved cartilage condition over time). These unitless rankings were used in a Sum of Ranks statistical analysis to compare cartilage changes across different knee joint regions without assuming normality (as appropriate for MRI data). There are no published standards for what would be considered a clinically significant effect for sum-of-ranks cartilage T2 data, so it was assumed that a statistically significant difference would imply clinical significance as well. |
| Number of Participants Who Convert to Alterative Treatment Within Each Group. | Any time during 18-month monitoring period. | Patients will be allowed to receive a steroid injection and still participate in the study. All participants that undergo alternative therapy (e.g. total knee arthroplasty or biologic injection) will be recorded, and proportions will be compared between groups. |
| Change in Physical Function of the Study Knee (Stair-Climbing Test) | 6 months, and 12 months (post 1st drug dose) | The Stair-Climbing Test assesses the time required (in seconds) to ascend and descend a standard flight of 10 stairs. Longer times indicate poorer physical function. Stairs require greater knee extensor force than gait, so this test may be more sensitive to osteoarthritis pain and function than walking tests. All post-intervention group comparisons were adjusted for the baseline value as a covariate. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Fisetin Fisetin 100 mg capsules (\
20 mg/ kg/ day) will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. A second course will be given for two consecutive days (days 31 and 32)
Fisetin: Fisetin will be administered orally at 20 mg/kg for two consecutive days, followed by 28 days off, then 2 more consecutive days. | 34 |
| Placebo Placebo capsules will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. A second course will be given for two consecutive days (days 31 and 32)
Placebo oral capsule: Placebo will be administered orally for two consecutive days, followed by 28 days off, then 2 more consecutive days. | 40 |
| Total | 74 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 5 | 2 |
| Overall Study | Physician Decision | 0 | 1 |
| Overall Study | Protocol Violation | 1 | 1 |
| Overall Study | Withdrawal by Subject | 3 | 1 |
Baseline characteristics
| Characteristic | Fisetin | Total | Placebo |
|---|---|---|---|
| Age, Continuous | 62 years | 63 years | 64 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 2 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 33 Participants | 72 Participants | 39 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) White | 34 Participants | 72 Participants | 38 Participants |
| Region of Enrollment United States | 34 participants | 74 participants | 40 participants |
| Sex: Female, Male Female | 20 Participants | 44 Participants | 24 Participants |
| Sex: Female, Male Male | 14 Participants | 30 Participants | 16 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 34 | 0 / 40 |
| other Total, other adverse events | 28 / 34 | 33 / 40 |
| serious Total, serious adverse events | 2 / 34 | 2 / 40 |
Outcome results
Primary
Number of Participants Experiencing One or More Treatment-Emergent Adverse Event
Number of Participants Experiencing one or more Treatment-Emergent Adverse Event (TEAE) within each group.
Time frame: Duration of study, an average of 12 months
Population: All participants randomized and dosed with study medication.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Fisetin | Number of Participants Experiencing One or More Treatment-Emergent Adverse Event | 28 Participants |
| Placebo | Number of Participants Experiencing One or More Treatment-Emergent Adverse Event | 33 Participants |
Comparison: Null hypothesis: no difference in proportion of participants experiencing any TEAE between Fisetin and Placebo groups.p-value: >0.995% CI: [0.25, 4.02]Fisher Exact
Secondary
Change in Levels of Cartilage Degenerating Markers Associated With OA
Serum cartilage oligomeric matrix protein (COMP) level measured on ELISA. All post-intervention group comparisons were adjusted for the baseline value as a covariate.
Time frame: 14 days, 45 days, 6 months, 12 months (post 1st drug dose)
Population: The analysis dataset is comprised of all randomized study participants with an evaluable endpoint data captured at each assessment time point. Unavailability of endpoint data at post-intervention time points may be due to withdrawal, discontinuation, missed study visit, or otherwise unsuccessful data acquisition or processing.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Fisetin | Change in Levels of Cartilage Degenerating Markers Associated With OA | COMP: Day 14 | 288.3 ng/ml | Standard Error 19 |
| Fisetin | Change in Levels of Cartilage Degenerating Markers Associated With OA | COMP: Month 6 | 282.0 ng/ml | Standard Error 22 |
| Fisetin | Change in Levels of Cartilage Degenerating Markers Associated With OA | COMP: Day 45 | 274.2 ng/ml | Standard Error 18.1 |
| Fisetin | Change in Levels of Cartilage Degenerating Markers Associated With OA | COMP: Month 12 | 274.9 ng/ml | Standard Error 14.1 |
| Placebo | Change in Levels of Cartilage Degenerating Markers Associated With OA | COMP: Month 12 | 268.0 ng/ml | Standard Error 12.7 |
| Placebo | Change in Levels of Cartilage Degenerating Markers Associated With OA | COMP: Day 14 | 290.1 ng/ml | Standard Error 17.5 |
| Placebo | Change in Levels of Cartilage Degenerating Markers Associated With OA | COMP: Day 45 | 285.2 ng/ml | Standard Error 15.6 |
| Placebo | Change in Levels of Cartilage Degenerating Markers Associated With OA | COMP: Month 6 | 241.7 ng/ml | Standard Error 18.2 |
Comparison: DAY 14 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-49.4, 54.5]Mixed Models Analysis
Comparison: DAY 45 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-36.8, 58.8]Mixed Models Analysis
Comparison: MONTH 6 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: 0.659495% CI: [-97.6, 17.1]Mixed Models Analysis
Comparison: MONTH 12 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-45.5, 31.7]Mixed Models Analysis
Secondary
Change in Levels of Pro-inflammatory Markers Associated With Senescence
Serum C-reactive protein (CRP) level measured on ELISA. The enzyme linked immunoassay (ELISA) is a laboratory technique that detects certain antigens in the blood. ELISA was used to detect the level of CRP in the blood. The liver releases CRP into blood in response to inflammation. All post-intervention group comparisons were adjusted for the baseline value as a covariate.
Time frame: 14 days, 45 days, 6 months, 12 months (post 1st drug dose)
Population: The analysis dataset is comprised of all randomized study participants with an evaluable endpoint data captured at each assessment time point. Unavailability of endpoint data at post-intervention time points may be due to withdrawal, discontinuation, missed study visit, or otherwise unsuccessful data acquisition or processing.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Fisetin | Change in Levels of Pro-inflammatory Markers Associated With Senescence | C-reactive protein (CRP): Day 14 | 14.0 ug/ml | Standard Error 2.5 |
| Fisetin | Change in Levels of Pro-inflammatory Markers Associated With Senescence | C-reactive protein (CRP): Day 45 | 8.9 ug/ml | Standard Error 1.9 |
| Fisetin | Change in Levels of Pro-inflammatory Markers Associated With Senescence | C-reactive protein (CRP): Month 6 | 32.5 ug/ml | Standard Error 6.4 |
| Fisetin | Change in Levels of Pro-inflammatory Markers Associated With Senescence | C-reactive protein (CRP): Month 12 | 9.2 ug/ml | Standard Error 1.8 |
| Placebo | Change in Levels of Pro-inflammatory Markers Associated With Senescence | C-reactive protein (CRP): Month 12 | 8.8 ug/ml | Standard Error 1.6 |
| Placebo | Change in Levels of Pro-inflammatory Markers Associated With Senescence | C-reactive protein (CRP): Day 14 | 10.5 ug/ml | Standard Error 2.5 |
| Placebo | Change in Levels of Pro-inflammatory Markers Associated With Senescence | C-reactive protein (CRP): Month 6 | 12.0 ug/ml | Standard Error 5.7 |
| Placebo | Change in Levels of Pro-inflammatory Markers Associated With Senescence | C-reactive protein (CRP): Day 45 | 6.4 ug/ml | Standard Error 1.8 |
Comparison: DAY 14 ASSESSMENT Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: 0.972895% CI: [-10.6, 3.6]Mixed Models Analysis
Comparison: DAY 45 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: 0.972895% CI: [-7.8, 2.8]Mixed Models Analysis
Comparison: MONTH 6 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: 0.082995% CI: [-37.7, -3.3]Mixed Models Analysis
Comparison: MONTH 12 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: 0.9728Contrast of LS Means
Secondary
Change in Muscle Strength (Isokinetic Dynamometry)
This test utilizes an isokinetic dynamometer to assess the peak knee extension torque that can be produced by the affected leg at a constant rate of knee extension (60 degrees/s). The resulting measure is normalized by body mass and reported with units Newton-meters (Nm). Increased torque over time would indicate improved muscle strength and/or decreased joint pain. All post-intervention group comparisons were adjusted for the baseline value as a covariate.
Time frame: 6 months, and 12 months (post 1st drug dose)
Population: The analysis dataset is comprised of all randomized study participants with an evaluable endpoint data captured at each assessment time point. Unavailability of endpoint data at post-intervention time points may be due to withdrawal, discontinuation, missed study visit, or otherwise unsuccessful data acquisition or processing.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Fisetin | Change in Muscle Strength (Isokinetic Dynamometry) | Quad Torque (affected): Month 6 | 81.2 Newton-meters (Nm) | Standard Error 2.6 |
| Fisetin | Change in Muscle Strength (Isokinetic Dynamometry) | Quad Torque (affected): Month 12 | 81.2 Newton-meters (Nm) | Standard Error 2.6 |
| Placebo | Change in Muscle Strength (Isokinetic Dynamometry) | Quad Torque (affected): Month 6 | 83.1 Newton-meters (Nm) | Standard Error 2.3 |
| Placebo | Change in Muscle Strength (Isokinetic Dynamometry) | Quad Torque (affected): Month 12 | 85.0 Newton-meters (Nm) | Standard Error 2.3 |
Comparison: MONTH 6 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: 0.590595% CI: [-5.07, 8.84]Mixed Models Analysis
Comparison: MONTH 12 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: 0.541495% CI: [-3.08, 10.79]Mixed Models Analysis
Secondary
Change in Physical Function of the Study Knee (6 Min Walk)
The 6 minute walk test (6MWT) assesses distance (in meters) walked over 6 minutes as a sub-maximal test of aerobic capacity, exercise tolerance and endurance. The score range for healthy adults is 400-700 m, depending on age and sex. Shorter distances indicate increased impairment. All post-intervention group comparisons were adjusted for the baseline value as a covariate.
Time frame: 6 months, and 12 months (post 1st drug dose)
Population: The analysis dataset is comprised of all randomized study participants with an evaluable endpoint data captured at each assessment time point. Unavailability of endpoint data at post-intervention time points may be due to withdrawal, discontinuation, missed study visit, or otherwise unsuccessful data acquisition or processing.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Fisetin | Change in Physical Function of the Study Knee (6 Min Walk) | Walk Distance: Month 6 | 541.8 Meters | Standard Error 8.7 |
| Fisetin | Change in Physical Function of the Study Knee (6 Min Walk) | Walk Distance: Month 12 | 544.2 Meters | Standard Error 8 |
| Placebo | Change in Physical Function of the Study Knee (6 Min Walk) | Walk Distance: Month 6 | 552.2 Meters | Standard Error 7.8 |
| Placebo | Change in Physical Function of the Study Knee (6 Min Walk) | Walk Distance: Month 12 | 543.6 Meters | Standard Error 7.2 |
Comparison: MONTH 6 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: 0.74895% CI: [-12.9, 33.9]Mixed Models Analysis
Comparison: MONTH 12 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: 0.957295% CI: [-22.2, 21.1]Mixed Models Analysis
Secondary
Change in Physical Function of the Study Knee (Fast 4-meter Walk)
fast 4-meter walk test (4MW). The 4MW was assessed at the fastest safe speed for each participant. This test assesses the capacity for performance of certain activities (e.g., crossing a street before the light changes). Units are m/s, and slower speeds indicate greater impairment. All post-intervention group comparisons were adjusted for the baseline value as a covariate.
Time frame: 6 months, and 12 months (post 1st drug dose)
Population: The analysis dataset is comprised of all randomized study participants with an evaluable endpoint data captured at each assessment time point. Unavailability of endpoint data at post-intervention time points may be due to withdrawal, discontinuation, missed study visit, or otherwise unsuccessful data acquisition or processing.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Fisetin | Change in Physical Function of the Study Knee (Fast 4-meter Walk) | Walk Time: Month 6 | 22.1 meters/second | Standard Error 0.46 |
| Fisetin | Change in Physical Function of the Study Knee (Fast 4-meter Walk) | Walk Time: Month 12 | 21.7 meters/second | Standard Error 0.36 |
| Placebo | Change in Physical Function of the Study Knee (Fast 4-meter Walk) | Walk Time: Month 6 | 21.7 meters/second | Standard Error 0.41 |
| Placebo | Change in Physical Function of the Study Knee (Fast 4-meter Walk) | Walk Time: Month 12 | 21.8 meters/second | Standard Error 0.32 |
Comparison: MONTH 6 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-1.61, 0.87]Mixed Models Analysis
Comparison: MONTH 12 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-0.8, 1.13]Mixed Models Analysis
Secondary
Change in Physical Function of the Study Knee (LEK)
Peak knee adduction moment (KAM) during stance phase of gait in the affected leg, determined using video-motion analysis and force plate data. Values are normalized by mass\*height of participant. Higher KAM has been associated with more rapid osteoarthritis progression. All post-intervention group comparisons were adjusted for the baseline value as a covariate.
Time frame: 6 months, and 12 months (post 1st drug dose)
Population: The analysis dataset is comprised of all randomized study participants with an evaluable endpoint data captured at each assessment time point. Unavailability of endpoint data at post-intervention time points may be due to withdrawal, discontinuation, missed study visit, or otherwise unsuccessful data acquisition or processing.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Fisetin | Change in Physical Function of the Study Knee (LEK) | Adduction Moment (affected): Month 6 | 0.204 Newton*meter / (kilogram*meter) | Standard Error 0.009 |
| Fisetin | Change in Physical Function of the Study Knee (LEK) | Adduction Moment (affected): Month 12 | 0.204 Newton*meter / (kilogram*meter) | Standard Error 0.009 |
| Placebo | Change in Physical Function of the Study Knee (LEK) | Adduction Moment (affected): Month 6 | 0.182 Newton*meter / (kilogram*meter) | Standard Error 0.008 |
| Placebo | Change in Physical Function of the Study Knee (LEK) | Adduction Moment (affected): Month 12 | 0.180 Newton*meter / (kilogram*meter) | Standard Error 0.009 |
Comparison: MONTH 6 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: 0.1395% CI: [-0.045, 0.002]Mixed Models Analysis
Comparison: MONTH 12 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: 0.1395% CI: [-0.049, 0.002]Mixed Models Analysis
Secondary
Change in Physical Function of the Study Knee (Stair-Climbing Test)
The Stair-Climbing Test assesses the time required (in seconds) to ascend and descend a standard flight of 10 stairs. Longer times indicate poorer physical function. Stairs require greater knee extensor force than gait, so this test may be more sensitive to osteoarthritis pain and function than walking tests. All post-intervention group comparisons were adjusted for the baseline value as a covariate.
Time frame: 6 months, and 12 months (post 1st drug dose)
Population: The analysis dataset is comprised of all randomized study participants with an evaluable endpoint data captured at each assessment time point. Unavailability of endpoint data at post-intervention time points may be due to withdrawal, discontinuation, missed study visit, or otherwise unsuccessful data acquisition or processing.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Fisetin | Change in Physical Function of the Study Knee (Stair-Climbing Test) | Stairs Time: Month 6 | 8.88 seconds | Standard Error 0.23 |
| Fisetin | Change in Physical Function of the Study Knee (Stair-Climbing Test) | Stairs Time: Month 12 | 8.66 seconds | Standard Error 0.3 |
| Placebo | Change in Physical Function of the Study Knee (Stair-Climbing Test) | Stairs Time: Month 6 | 8.66 seconds | Standard Error 0.21 |
| Placebo | Change in Physical Function of the Study Knee (Stair-Climbing Test) | Stairs Time: Month 12 | 8.78 seconds | Standard Error 0.27 |
Comparison: MONTH 6 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: 0.958495% CI: [-0.84, 0.4]Mixed Models Analysis
Comparison: MONTH 12 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: 0.958495% CI: [-0.69, 0.92]Mixed Models Analysis
Secondary
Change in Physical Function of the Study Knee (Timed-up-and-go Test)
The Timed Up and Go (TUG) test measures how long it takes (in seconds) to stand up, walk a distance of 10 feet, turn, walk back, and sit down again. \< 10 seconds is considered normal. Longer times indicate poorer function. All post-intervention group comparisons were adjusted for the baseline value as a covariate.
Time frame: 6 months, and 12 months (post 1st drug dose)
Population: The analysis dataset is comprised of all randomized study participants with an evaluable endpoint data captured at each assessment time point. Unavailability of endpoint data at post-intervention time points may be due to withdrawal, discontinuation, missed study visit, or otherwise unsuccessful data acquisition or processing.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Fisetin | Change in Physical Function of the Study Knee (Timed-up-and-go Test) | Up and go time: Month 6 | 6.08 seconds | Standard Error 0.18 |
| Fisetin | Change in Physical Function of the Study Knee (Timed-up-and-go Test) | Up and go time: Month 12 | 5.93 seconds | Standard Error 0.15 |
| Placebo | Change in Physical Function of the Study Knee (Timed-up-and-go Test) | Up and go time: Month 6 | 6.09 seconds | Standard Error 0.16 |
| Placebo | Change in Physical Function of the Study Knee (Timed-up-and-go Test) | Up and go time: Month 12 | 6.00 seconds | Standard Error 0.13 |
Comparison: MONTH 6 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-0.47, 0.49]Mixed Models Analysis
Comparison: MONTH 12 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-0.33, 0.47]Mixed Models Analysis
Secondary
Change in the Quality of Articular Cartilage in the Study Knee With Quantitative Magnetic Resonance Imaging (MRI)
Mean T2 relaxation times were determined across 4 subregions: central medial femur (CMF), central lateral femur (CLF), central medial tibia (CMT), and central lateral tibia (CLT). All post-intervention group comparisons were adjusted for the baseline value as a covariate. The mean T2 changes over time for all subregions were listed in rank order from most positive (indicating worsened cartilage condition over time) to most negative (indicating improved cartilage condition over time). These unitless rankings were used in a Sum of Ranks statistical analysis to compare cartilage changes across different knee joint regions without assuming normality (as appropriate for MRI data). There are no published standards for what would be considered a clinically significant effect for sum-of-ranks cartilage T2 data, so it was assumed that a statistically significant difference would imply clinical significance as well.
Time frame: 6 months, and 12 months (post 1st drug dose)
Population: The analysis dataset is comprised of all randomized study participants with an evaluable endpoint data captured at each assessment time point. Unavailability of endpoint data at post-intervention time points may be due to withdrawal, discontinuation, missed study visit, or otherwise unsuccessful data acquisition or processing.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Fisetin | Change in the Quality of Articular Cartilage in the Study Knee With Quantitative Magnetic Resonance Imaging (MRI) | Sum of Ranks Mean T2: Month 6 | 149.6 Unitless | Standard Error 11.6 |
| Fisetin | Change in the Quality of Articular Cartilage in the Study Knee With Quantitative Magnetic Resonance Imaging (MRI) | Sum of Ranks Mean T2: Month 12 | 156.1 Unitless | Standard Error 13 |
| Placebo | Change in the Quality of Articular Cartilage in the Study Knee With Quantitative Magnetic Resonance Imaging (MRI) | Sum of Ranks Mean T2: Month 6 | 150.3 Unitless | Standard Error 10.7 |
| Placebo | Change in the Quality of Articular Cartilage in the Study Knee With Quantitative Magnetic Resonance Imaging (MRI) | Sum of Ranks Mean T2: Month 12 | 144.8 Unitless | Standard Error 12 |
Comparison: MONTH 6 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.~A priori power calculation was based a standardized mean difference effect size of SMD=0.73 (Mackay, et al, 2018, Osteoarthritis and Cartilage).p-value: >0.9995% CI: [-30.95, 32.3]Mixed Models Analysis
Comparison: MONTH 12 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.~A priori power calculation was based a standardized mean difference effect size of SMD=0.73 (Mackay, et al, 2018, Osteoarthritis and Cartilage).p-value: >0.9995% CI: [-46.9, 24.2]Mixed Models Analysis
Secondary
Evaluation of Patient Reported Outcomes (PROs) for Knee Function
Western Ontario and McMaster Universities Arthritis Index (WOMAC) - total score. Scores range from 0 to 96 for the total WOMAC where 0 represents the best health status and 96 the worst possible status. The higher the score, the poorer the function. All post-intervention group comparisons were adjusted for the baseline value as a covariate.
Time frame: 6 months, 12 months, and 18 months (post 1st drug dose)
Population: The analysis dataset is comprised of all randomized study participants with an evaluable endpoint data captured at each assessment time point. Unavailability of endpoint data at post-intervention time points may be due to withdrawal, discontinuation, missed study visit, or otherwise unsuccessful data acquisition or processing.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Function | WOMAC Total: Month 12 | 19.6 score on a scale | Standard Error 2.1 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Function | WOMAC Total: Month 6 | 15.2 score on a scale | Standard Error 1.8 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Function | WOMAC Total: Month 18 | 17.4 score on a scale | Standard Error 2 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Function | WOMAC Total: Month 6 | 17.1 score on a scale | Standard Error 1.7 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Function | WOMAC Total: Month 12 | 15.4 score on a scale | Standard Error 1.9 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Function | WOMAC Total: Month 18 | 17.4 score on a scale | Standard Error 1.8 |
Comparison: MONTH 6 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: 0.910695% CI: [-3.09, 6.82]Mixed Models Analysis
Comparison: MONTH 12 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: 0.442495% CI: [-9.93, 1.53]Mixed Models Analysis
Comparison: MONTH 18 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: 0.990195% CI: [-5.55, 5.48]Mixed Models Analysis
Secondary
Evaluation of Patient Reported Outcomes (PROs) for Knee Pain
Numeric Rating Scale (NRS) reporting 'pain today'. Scale of 0-10 with 0 representing 'no pain' and 10 representing 'severe pain'. All post-intervention group comparisons were adjusted for the baseline value as a covariate.
Time frame: every 3 days for the first 6-weeks of drug dosing, then weekly for an additional 6 weeks.
Population: The analysis dataset is comprised of all randomized study participants with an evaluable endpoint data captured at each assessment time point. Unavailability of endpoint data at post-intervention time points may be due to withdrawal, discontinuation, missed study visit, or otherwise unsuccessful data acquisition or processing.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 3 | 2.80 score on a scale | Standard Error 0.29 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 6 | 2.43 score on a scale | Standard Error 0.33 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 9 | 2.35 score on a scale | Standard Error 0.41 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 12 | 2.47 score on a scale | Standard Error 0.31 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 15 | 2.65 score on a scale | Standard Error 0.37 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 18 | 2.58 score on a scale | Standard Error 0.36 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 21 | 2.25 score on a scale | Standard Error 0.29 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 24 | 2.46 score on a scale | Standard Error 0.32 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 27 | 2.35 score on a scale | Standard Error 0.28 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 30 | 2.58 score on a scale | Standard Error 0.3 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 33 | 2.09 score on a scale | Standard Error 0.29 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 36 | 2.57 score on a scale | Standard Error 0.3 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 39 | 2.15 score on a scale | Standard Error 0.3 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 42 | 2.42 score on a scale | Standard Error 0.28 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Week 7 | 2.15 score on a scale | Standard Error 0.29 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Week 8 | 2.04 score on a scale | Standard Error 0.25 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Week 9 | 1.84 score on a scale | Standard Error 0.24 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Week 10 | 1.88 score on a scale | Standard Error 0.29 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Week 11 | 1.99 score on a scale | Standard Error 0.28 |
| Fisetin | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Week 12 | 2.26 score on a scale | Standard Error 0.39 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Week 10 | 1.71 score on a scale | Standard Error 0.26 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 3 | 2.85 score on a scale | Standard Error 0.27 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 33 | 2.19 score on a scale | Standard Error 0.27 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 6 | 2.87 score on a scale | Standard Error 0.3 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Week 8 | 1.84 score on a scale | Standard Error 0.23 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 9 | 2.77 score on a scale | Standard Error 0.37 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 36 | 2.37 score on a scale | Standard Error 0.27 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 12 | 2.40 score on a scale | Standard Error 0.28 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Week 12 | 1.91 score on a scale | Standard Error 0.36 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 15 | 2.18 score on a scale | Standard Error 0.35 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 39 | 2.26 score on a scale | Standard Error 0.27 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 18 | 2.39 score on a scale | Standard Error 0.32 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Week 9 | 1.86 score on a scale | Standard Error 0.22 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 21 | 2.44 score on a scale | Standard Error 0.26 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 42 | 1.81 score on a scale | Standard Error 0.24 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 24 | 2.57 score on a scale | Standard Error 0.29 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Week 11 | 1.57 score on a scale | Standard Error 0.25 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 27 | 2.36 score on a scale | Standard Error 0.25 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Week 7 | 1.92 score on a scale | Standard Error 0.26 |
| Placebo | Evaluation of Patient Reported Outcomes (PROs) for Knee Pain | NRS Pain Today: Day 30 | 2.21 score on a scale | Standard Error 0.27 |
Comparison: DAY 3 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-0.75, 0.85]Mixed Models Analysis
Comparison: DAY 6 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-0.45, 1.34]Mixed Models Analysis
Comparison: DAY 9 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-0.7, 1.54]Mixed Models Analysis
Comparison: DAY 12 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-0.91, 0.78]Mixed Models Analysis
Comparison: DAY 15 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-1.5, 0.56]Mixed Models Analysis
Comparison: DAY 18 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-1.16, 0.77]Mixed Models Analysis
Comparison: DAY 21 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-0.58, 0.96]Mixed Models Analysis
Comparison: DAY 24 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-0.76, 0.97]Mixed Models Analysis
Comparison: DAY 27 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-0.74, 0.76]Mixed Models Analysis
Comparison: DAY 30 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-1.2, 0.44]Mixed Models Analysis
Comparison: DAY 33 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-0.69, 0.89]Mixed Models Analysis
Comparison: DAY 36 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-1.02, 0.61]Mixed Models Analysis
Comparison: DAY 39 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-0.7, 0.92]Mixed Models Analysis
Comparison: DAY 42 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-1.36, 0.13]Mixed Models Analysis
Comparison: WEEK 7 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-1.01, 0.55]Mixed Models Analysis
Comparison: WEEK 8 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-0.89, 0.49]Mixed Models Analysis
Comparison: WEEK 9 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-0.63, 0.67]Mixed Models Analysis
Comparison: WEEK 10 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-0.95, 0.61]Mixed Models Analysis
Comparison: WEEK 11 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-1.18, 0.34]Mixed Models Analysis
Comparison: WEEK 12 ASSESSMENT. Null hypothesis: no difference in baseline-adjusted least squares means between Fisetin and Placebo groups at each post-intervention assessment.p-value: >0.9995% CI: [-1.41, 0.71]Mixed Models Analysis
Secondary
Number of Participants Who Convert to Alterative Treatment Within Each Group.
Patients will be allowed to receive a steroid injection and still participate in the study. All participants that undergo alternative therapy (e.g. total knee arthroplasty or biologic injection) will be recorded, and proportions will be compared between groups.
Time frame: Any time during 18-month monitoring period.
Population: The analysis dataset is comprised of all randomized study participants.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Fisetin | Number of Participants Who Convert to Alterative Treatment Within Each Group. | 1 Participants |
| Placebo | Number of Participants Who Convert to Alterative Treatment Within Each Group. | 3 Participants |
Comparison: With only 4 participants that converted to an alternative treatment modality, this analysis is underpowered.p-value: 0.47495% CI: [0.05, 4.21]Log Rank